Prelude Therapeutics Q1 EPS $(0.13) Beats $(0.25) Estimate, Sales $4.580M

Prelude Therapeutics, Inc.

Prelude Therapeutics, Inc.

PRLD

0.00

Prelude Therapeutics (NASDAQ: PRLD) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.25) by 48 percent. This is a 69.05 percent increase over losses of $(0.42) per share from the same period last year. The company reported $4.580 million in sales this quarter.